The Delaware Court of Chancery determined, among other things, that PharmAthene, Inc. is entitled to a lump sum damage award in a still unspecified amount, with interest and fees, based on U. S. Government purchases of SIGA's smallpox drug supposedly anticipated in 2006.The total award is likely to be substantial, but it will not be established until after the Delaware Court of Chancery considers certain calculations from experts and the agreement or input of each of SIGA and PharmAthene, Inc
"This is no rooky company. I think it will be taken out buy a major player."
How ironic that one of the most idiotic statements I've seen on this board, just happens to be made in response to the one holding the previous crown, (and my #1 fan) drod! Can't make this stuff up, lol.
people are realizing how bad viruses can get. The African out break is just a step away from hitting the west. If this goes air born we will be in trouble. That's the only thing stopping this. Anti Virus treatments of every company will be evaluated. Look at this stocks past and national stock piles. This is no rooky company. I think it will be taken out buy a major player.
You are so foolish to look at things with only one eye open. You lose perspective, depth of field and dimension. To start, the fact that BARDA cut the order from 14 million courses to 2 million has nothing to do with what was expected in 2006. What was expected in 2006, 14 million courses at a minimum, what was it that BARDA subsequently ordered . . . wait . . . for . . . it . . . oh wait, you want to ignore facts and live in your own pretend world where SIGA doesn't have to pay the consequences for its bad faith actions.
You see the much higher figures that both SIGA and PIP had hoped for were due to the fact that many with compromised immune systems (e.g. cancer patient, patients with auto immune disorders, HIV, etc) may not have been appropriate candidates for the initial vaccine the government stockpiled. That's why there was hope for even larger orders in some models, along with international sales. But let's just pretend that because there were various models with widely varying assumptions that a single estimate of 14 million courses is speculative. Keep covering your eyes and your ears and hoping to wake up in Kansas! Tota is dead and your alone, but you don't know it!
With your logic, because SIGA is using some ridiculous accounting to claim that from an economic perspective they have not satisfied contractual obligations--even though they have manufactured, made delivery, delivery has satisfied contractual requirements to be received, it has been received and SIGA has been sent the cash--it not real? We can't be certain they are going to make money on the contract. All that has done is to leave their investors in the dark about what they can reasonably expect to make on not just this contract, but the next. SIGA is nearly done making deliveries and yet by looking at their financials you can't tell if it would even be worth it for them to bid on the next contract let alone win it! That's a ROSE/SIGA problem not a Parsons/BARDA problem.
for a long, long time. what has management done to counter this recent 50% drop? promote their Ebola drug? make good on "partnership" promises? reduce the O/H costs, via lower salaries? Or just sit around and do nothing, as usual, and collect their WAY over market rate salaries?
The mention from Forbes..as vague as one would expect:
"SIGA (NASDAQ:SIGA) is an anti-infective company headquartered in New York is working closely with federal agencies to develop a range of compounds that target diseases that could be used as bioweapons, such as smallpox. The company has one compound that it is developing to target filo-viruses such as Ebola.
SIGA uses analytical tools to evaluate the bacterial and viral genomes to find new targets against these bugs. The company is currently testing three different experimental drugs. SIGA’s compounds work by trying to prevent the Ebola virus from entering host cells. This would block the ability of the virus to replicate."
5 Years ago I would have said FIRE.
SIGA is a much different company then it was 5 years ago.
Ah...the good old days.
Perelman......where are you?
Over 1200 dead, curfews, quarantines and no way to actively treat the needy. When asked, an official from the WHO said they have no idea what kind of money it would require to solve the problem. SIGA has been mentioned multiple times, including the Forbes article yesterday. Smoke or Fire?
Oh, I see. So.....It wasn't speculative that 14+ million courses would be ordered back in 2006 and JUST 8-years later there is no where near this number. So 14+ million was a given, yet it hasn't happened and there is nothing stating sales ever be such. Therefore, pay the piper on the 14+ million because it isn't speculative. NOW, I understand. So easy!!
Thank you. What do you think of MZOR, I think will start to trend up. I am looking for entry under 13.00. I think you will really like this company. I will take a look at APT. Thanks much success
Just 3 times average volume today. WEDS and THURS had better volume. The best part was the ones that bought were on the ask and paying up. That was very good.
The WHO doesn't have to put in a HUGE order...SIGA's name just needs to keep being mentioned in all of these Ebola articles. That's a start...Where it goes from there is what the market is for...Even with Ferguson/Gaza/ISIS/Ukraine etc. the Ebola mess is still making headlines, it's much worse than anyone on this continent realizes...
Your right, could be shorts covering. Otherwise known as dead cat bounce. #$%$ luck. Still think there is downside when damage amount is confirmed on expert report (preliminary), which could come end of this week or early next week but would require one of the companies to disclose contents. Otherwise it comes when Parson's issues final decision (likely a month or more out).
It's not speculative. It's based on "no-take" rate and U.S. population. Go look it up and get educated before your drool about current contract size. Expected damages are based on what could have been reasonably expected by PIP/SIGA in 2006.
SIGA never even filed an IND for any of the ST drugs except ST-246....
I doubt the WHO is going to put in a huge order with SIGA in the near future....